Ossianix

Executive Summary

Ossianix is a UK-based biotechnology company pioneering the use of shark-derived single-domain antibodies (VNARs) to develop biologics capable of crossing the blood-brain barrier (BBB). Founded in 2012 and based in Oxford, the company's core proprietary platform, the TXP1 Brain Shuttle, enables targeted delivery of therapeutic payloads to the brain, addressing a critical challenge in treating central nervous system (CNS) disorders. By leveraging the unique properties of VNARs—small size, high stability, and natural BBB penetrance—Ossianix aims to create a new class of CNS therapeutics for indications such as neurodegenerative diseases, brain tumors, and other neurological conditions. The company operates in the growing fields of antibodies and biologics, with a focus on overcoming the limitations of traditional large-molecule drugs in crossing the BBB.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data for Lead CNS Program60% success
• Q2 2027Strategic Partnership or Licensing Deal for TXP1 Platform40% success
• Q1 2027Series A or B Financing Round50% success